US-based company that deals with AI-powered commercialisation solutions for the pharmaceutical, life sciences and biotech industries Anervea.ai announced on Monday that it has named Jack Capponi as its new chief commercial officer (CCO) and a member of the board of directors.

Capponi brings over 20 years of leadership experience, having successfully launched 13 global products in oncology, rare diseases and neuroscience. His expertise in product commercialization and market access, gained from roles at Syneos, Bausch, and Amgen, will support Anervea's expansion into US and EU markets.

Anervea's AI, machine learning, and data science capabilities, combined with its work along side companies like Sanofi and Pfizer, strengthen its competitive position. Capponi's leadership will drive the commercialization of Anervea's flagship platforms, Alfa CI and Alfa Sage. Alfa CI provides real-time competitive intelligence, while Alfa Sage delivers conversational analytics for rapid data insights. His appointment enhances Anervea's global growth potential and innovation in the pharma and biotech sectors.